Complement activation induces excessive T cell cytotoxicity in severe COVID-19
Authors
- P. Georg
- R. Astaburuaga-García
- L. Bonaguro
- S. Brumhard
- L. Michalick
- L.J. Lippert
- T. Kostevc
- C. Gäbel
- M. Schneider
- M. Streitz
- V. Demichev
- I. Gemünd
- M. Barone
- P. Tober-Lau
- E.T. Helbig
- D. Hillus
- L. Petrov
- J. Stein
- H.P. Dey
- D. Paclik
- C. Iwert
- M. Mülleder
- S.K. Aulakh
- S. Djudjaj
- R.D. Bülow
- H.E. Mei
- A.R. Schulz
- A. Thiel
- S. Hippenstiel
- A.E. Saliba
- R. Eils
- I. Lehmann
- M.A. Mall
- S. Stricker
- J. Röhmel
- V.M. Corman
- D. Beule
- E. Wyler
- M. Landthaler
- B. Obermayer
- S. von Stillfried
- P. Boor
- M. Demir
- H. Wesselmann
- N. Suttorp
- A. Uhrig
- H. Müller-Redetzky
- J. Nattermann
- W.M. Kuebler
- C. Meisel
- M. Ralser
- J.L. Schultze
- A.C. Aschenbrenner
- C. Thibeault
- F. Kurth
- L.E. Sander
- N. Blüthgen
- B. Sawitzki
Journal
- Cell
Citation
- Cell 185 (3): 493-512
Abstract
Severe COVID-19 is linked to both dysfunctional immune response and unrestrained immunopathology, and it remains unclear whether T cells contribute to disease pathology. Here, we combined single-cell transcriptomics and single-cell proteomics with mechanistic studies to assess pathogenic T cell functions and inducing signals. We identified highly activated, CD16(+) T cells with increased cytotoxic functions in severe COVID-19. CD16 expression enabled immune complex-mediated, T cell receptor-independent degranulation and cytotoxicity not found in other diseases. CD16(+) T cells from COVID-19 patients promoted microvascular endothelial cell injury and release of neutrophil and monocyte chemoattractants. CD16(+) T cell clones persisted beyond acute disease maintaining their cytotoxic phenotype. Increased generation of C3a in severe COVID-19 induced activated CD16(+) cytotoxic T cells. Proportions of activated CD16(+) T cells and plasma levels of complement proteins upstream of C3a were associated with fatal outcome of COVID-19, supporting a pathological role of exacerbated cytotoxicity and complement activation in COVID-19.